{
    "root": "35ce99f0-8af9-4660-e063-6294a90a54bf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Temozolomide",
    "value": "20250523",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TEMOZOLOMIDE",
            "code": "YF1K15M17Y"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "Temozolomide is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma. ( 1.2 ) Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma.( 1.2 ) Treatment of adults with refractory anaplastic astrocytoma. ( 1.2 )",
    "contraindications": "Administer either orally or intravenously.( 2.4 ) Newly Diagnosed Glioblastoma : 75 mg/m 2 once daily for 42 to 49 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m 2 once daily for Days 1 to 5 of each 28-day cycle for 6 cycles. May increase maintenance dose to 200 mg/m 2 for Cycles 2 to 6 based on toxicity. ( 2.1 ) Provide Pneumocystis pneumonia (PCP) prophylaxis during concomitant phase and continue in patients who develop lymphopenia until resolution to Grade 1 or less. ( 2.1 ) Adjuvant Treatment of Newly Diagnosed Anaplastic Astrocytoma: Beginning 4 weeks after the end of radiotherapy, administer temozolomide capsules orally in a single dose on days 1-5 of a 28-day cycle for 12 cycles. The recommended dosage for Cycle 1 is 150 mg/m 2 per day and for Cycles 2 to 12 is 200 mg/m 2 if patient experienced no or minimal toxicity in Cycle 1. ( 2.2 ) Refractory Anaplastic Astrocytoma : Initial dose of 150 mg/m 2 once daily on Days 1 to 5 of each 28-day cycle. ( 2.2 )",
    "warningsAndPrecautions": "Temozolomide is a hazardous drug. Follow applicable special handling and disposal procedures.\n \n  1\n                  \n                  \n                     Temozolomide capsules, USP\n                  \n                  Temozolomide capsules, USP are supplied in amber glass bottles with child-resistant polypropylene caps and child-resistant sachet packs containing the following capsule strengths:\n                  \n                     Temozolomide Capsules 5 mg:have white bodies with green caps. The capsule body is imprinted with '5'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-048-53 \n    14 count – NDC 16729-048-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-048-31 \n    14 count – NDC 16729-048-04\n\n \n                  \n                     Temozolomide Capsules 20 mg:have white bodies with yellow caps. The capsule body is imprinted with '20'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-049-53 \n    14 count – NDC 16729-049-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-049-31 \n    14 count – NDC 16729-049-04\n\n \n                  \n                     Temozolomide Capsules 100 mg:have white bodies with pink caps. The capsule body is imprinted with '100'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-050-53 \n    14 count – NDC 16729-050-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-050-31 \n    14 count – NDC 16729-050-04\n\n \n                  \n                     Temozolomide Capsules 140 mg:have white bodies with transparent blue caps. The capsule body is imprinted with '140'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-129-53 \n    14 count – NDC 16729-129-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-129-31 \n    14 count – NDC 16729-129-04\n\n \n                  \n                     Temozolomide Capsules 180 mg:have white bodies with maroon caps. The capsule body is imprinted with '180'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-130-53 \n    14 count – NDC 16729-130-54 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-130-31 \n    14 count – NDC 16729-130-04\n\n \n                  \n                     Temozolomide Capsules 250 mg:have white bodies with white caps. The capsule body is imprinted with '250'. The cap is imprinted with 'TMZ'. \n    They are supplied as follows: \n    Amber Glass Bottles \n    5 count – NDC 16729-051-53 \n    Sachet Packs (Carton Contains Individual Sachet with One Capsule each): \n    5 count – NDC 16729-051-31\n\n \n                  Store temozolomide capsules at 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).",
    "adverseReactions": "Temozolomide is contraindicated in patients with a history of serious hypersensitivity reactions to:\n                  \n                  \n                     temozolomide or any other ingredients in temozolomide capsules; and\n                     dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3methyltriazen-1-yl)-imidazole-4-carboxamide.\n                  \n                  Reactions to temozolomide have included anaphylaxis\n \n  [see\n  \n   Adverse Reactions (6.2)]."
}